Ad
related to: moderna stock news update today in the philippines per region
Search results
Results From The WOW.Com Content Network
Moderna’s revenue fell 64% to just below $7 billion in 2023 (far below the $18.5 billion in sales reported in 2020), and the company reported a loss of roughly $12 per share.
Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years ...
Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro. ... as per data from Benzinga Pro. Recently, Moderna and several other ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month.
There was good news to share, but the market focused on a declining sales forecast and hammered the stock lower. Last November, Moderna said it expected 2024 revenue to land in a range between $3 ...
But Moderna's news hasn't been as bright recently. Last month, the company revised coronavirus vaccine revenue downward due to lower sales. And in its update this week, the biotech made ...
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...